FDA urges adherence to specified intervals of mRNA COVID-19 vaccines
The Food and Drug Administration yesterday reminded the public of the importance of receiving COVID-19 vaccines in accordance to their agency authorizations, a process that FDA said will safely provide the “remarkable” levels of protection observed during large, randomized clinical trials.
Both approved vaccines, of the mRNA type, are approved for administration via two separate doses, given at either three- or four-week intervals.
“The available data continue to support the use of two specified doses of each authorized vaccine at specified intervals,” FDA said.
Related News Articles
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…